Business Context and Reporting Period
Immatics N.V., a biopharmaceutical company, filed Form 6-K on November 12, 2025. The filing provides updated clinical data for two bispecific antibody candidates: IMA402 (PRAME) and IMA401 (MAGEA4/8). The data cutoff for the reported clinical results is September 26, 2025.
Key Financial Metrics
This filing is a clinical update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
IMA402 PRAME Bispecific
- Study Status: Phase 1a dose escalation completed; Phase 1b dose expansion ongoing.
- Patient Population: 80 heavily pre-treated patients with solid tumors treated; 20 efficacy-evaluable patients in the Recommended Phase 2 Dose (RP2D) range (10-30 mg).
- Safety: Favorable tolerability. Most frequent adverse events were transient lymphopenia and low-grade cytokine release syndrome (CRS). No Grade 3 CRS, ICANS, or Grade 5 events occurred.
- Efficacy (RP2D Range):
- Confirmed Objective Response Rate (cORR): 30% (6/20) overall; 29% (4/14) in melanoma.
- Responses included two complete metabolic responses in melanoma (ongoing 8 and 18 months) and one confirmed partial response in ovarian carcinoma.
- Median Progression-Free Survival (PFS): 4.8 months; 1-year Overall Survival (OS) rate: 94%.
IMA401 MAGEA4/8 Bispecific
- Study Status: Phase 1a dose escalation completed; provisional RP2D identified at 1-2 mg.
- Patient Population: 55 patients treated (46 monotherapy, 9 with pembrolizumab); 38 efficacy-evaluable at doses ≥1 mg.
- Safety: Favorable tolerability. No ICANS observed. Most frequent events were low-grade CRS and transient lymphopenia.
- Efficacy (≥1 mg):
- Head and Neck Cancer: cORR 25% (2/8).
- Melanoma: cORR 29% (2/7).
- Squamous Non-Small Cell Lung Cancer (sqNSCLC): 1 partial response observed in an ICI-resistant patient.
- Duration of response exceeded 6 months for all confirmed responders, with one ongoing over 2 years.
Guidance, Outlook, and Strategic Updates
- Development Plan: Advancing IMA402 into Phase 1b expansion in 2026 to determine final RP2D as monotherapy and in combination with immune checkpoint inhibitors, focusing on melanoma and gynecologic cancers.
- Combination Strategy: Exploring the combination of IMA402 and IMA401 in sqNSCLC, targeting a population where over 90% of patients are positive for PRAME and/or MAGEA4/8.
- Pipeline Prioritization: Deprioritized preclinical development of IMA204 (COL6A3 cell therapy) and the ACTallo allogeneic cell therapy platform to focus resources on clinical candidates.
- Market Opportunity: Estimated addressable patient population for metastatic sqNSCLC in the US and EU5 is approximately 40,000 patients per year.
Investor Verification Checklist
- Verify the specific endpoints and statistical significance of the reported 30% cORR for IMA402 in the small efficacy-evaluable cohort (n=20).
- Confirm the timeline and design details for the upcoming Phase 1b expansion cohorts in 2026.
- Assess the financial impact of deprioritizing the IMA204 and ACTallo programs on the company's long-term pipeline diversity.
- Review the safety data for the combination of IMA401 with pembrolizumab, noting the small sample size (n=9) in the combination arm.
- Monitor the progression of the two complete metabolic responses in melanoma to confirm durability beyond the current 8 and 18-month marks.